HS Pipeline Watch: Abbvie’s Lutikizumab Advances to Phase 3 in HS
Adults with moderate to severe hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy showed higher response rates in Hidradenitis Suppurativa Clinical Response 50 (HiSCR) at week 16 when treated with lutikizumab (ABT-981) 300 mg every other week or 300 mg compared to patients who received placebo, according to results from a new Phase 2 study. […]